Provention Bio, Inc. Securities Litigation

Filing Deadline: July 20, 2021

If you purchased a significant amount of shares of Provention Bio Inc. Common Stock (NASDAQ: PRVB), you have certain options. Investors should contact us before July 20, 2021.


Lawsuit Overview

Defendant:Provention Bio Inc. Common Stock
Date Filed:May 21st, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:November 2nd, 2020
Class End Date:April 8th, 2021

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Provention Bio Inc. Common Stock

First Identified Complaint

Adam Paxton, et al. v. Provention Bio, Inc., et al.

Date Filed:May 21st, 2021
Class Period Start:November 2nd, 2020
Class Period End:April 8th, 2021
First Identified Complaint Filings
#Document TitleFiling Date